Table of Contents
Executive Summary — 5
Belgium Pharmaceuticals And
Healthcare Industry SWOT — 6
Belgium Political
SWOT — 7
Belgium Economic SWOT — 7
Pharmaceutical Business Environment Ratings — 8
Table:
Western Europe Pharmaceutical Business Environment
Ratings — 8
Limits Of Potential
Returns — 9
Belgium – Market
Summary — 10
Regulatory Regime — 12
Intellectual Property Environment — 13
Pricing And
Reimbursement Regime — 13
Pricing And Reimbursement
Developments — 14
OTC Regulatory
Environment — 16
Industry
Developments — 17
Healthcare
Sector — 17
Recent Healthcare Sector
Developments — 18
Epidemiology — 19
Table: Disease Burden In Western Europe — 20
Generics
Sector — 21
Research And Development
Sector — 23
Industry Forecast
Scenario — 25
Overall Market
Forecast — 25
Table: Belgium’s Drug Market
Indicators, 2004-2013 — 26
Key Growth Factors –
Industry — 27
Table: Belgium’s Health Expenditure
Indicators, 2004-2013 — 28
Key Growth Factors –
Macroeconomic — 29
Table: Belgium - Economic Activity,
2005-2012 — 31
Prescription Market
Forecast — 31
Table: ATC Breakdown Prescription Drug
Market US$mn — 32
Patented Market
Forecast — 33
Table: Belgium’s Patented Drugs Market
Indicators, 2004-2013 — 33
OTC Market
Forecast — 34
Table: Belgium’s OTC Drugs Market
Indicators, 2004-2013 (US$mn unless otherwise stated) — 35
Generics Market Forecast — 35
Table: Belgium’s
Generics Drug Market Indicators, 2004-2013 — 36
Export/Import Forecasts — 37
Table: Belgium’s
Pharmaceuticals Exports And Imports, 2004-2013
(US$mn) — 38
Other Healthcare Data
Forecasts — 39
Table: Belgium’s Healthcare Data
Indicators, 2005-2012 — 39
Key Risks To BMI’s
Forecasts — 39
Competitive
Landscape — 40
Recent Company
Developments — 41
Company Monitor — 43
Leading Multinational Manufacturers — 43
GlaxoSmithKline
(GSK) — 43
Pfizer — 45
Novartis — 47
Sanofi-Aventis — 49
Merck & Co — 50
Leading Indigenous
Manufacturers — 52
UCB Pharma — 52
Solvay — 56
Janssen Pharmaceutica — 60
Omega Pharma — 62
Country Snapshot: Belgium Demographic
Data — 64
Section 1: Population — 64
Table: Demographic Indicators, 2005-2030 — 64
Table:
Rural/Urban Breakdown, 2005-2030 — 65
Section 2: Education
And Healthcare — 65
Table: Education,
2002-2005 — 65
Table: Vital Statistics,
2005-2030 — 65
Section 3: Labour Market And Spending
Power — 66
Table: Employment Indicators,
2001-2006 — 66
Table: Consumer Expenditure, 2000-2012
(US$) — 67
Table: Average Annual Wages,
2000-2012 — 67
BMI Forecast
Modelling — 68
How We Generate Our Pharmaceutical Industry
Forecasts — 68
Pharmaceutical Business Environment Ratings
Methodology — 69
Ratings Overview — 69
Table: Pharmaceutical Business Environment Indicators — 70
Weighting — 71
Table: Weighting Of
Components — 71
Sources — 71
| 
View Cart
